Phase 2 Study of Oral Emraclidine for Safety and Effectiveness in Adults With Schizophrenia

What this Trial Is About

Schizophrenia is a serious psychiatric illness marked by significant disturbances in thinking, language, perception, and self-awareness. Researchers are evaluating the safety, effects on disease activity, and how the investigational drug emraclidine is processed in the body in adults with schizophrenia. This is a Phase 2 study designed to explore these aspects with careful monitoring. Participants are divided into two parts. In Part A, participants receive different increasing doses of oral emraclidine or placebo for 14 to 21 days. In Part B, participants receive oral emraclidine or placebo for up to 42 days. Following treatment, all participants enter a 30-day safety follow-up to monitor any lasting effects. During the study, participants will attend regular clinic visits for medical exams, blood tests, and questionnaires to check for side effects and disease changes. Researchers will measure adverse events, drug levels in the blood, and changes in schizophrenia symptoms using specific scales. The total participation time may be up to about 74 days including treatment and follow-up.

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia